HIPEC FOR
OVARIAN CANCER
The OVHIPEC-1 trial changed standard of care — demonstrating that adding a 60-minute cisplatin HIPEC to interval debulking surgery improved overall survival by 12 months in advanced ovarian cancer with no increase in surgical complication rates.
analyticsAt a Glance
- check_circleOVHIPEC-1 (van Driel et al., NEJM 2018): OS improved from 33.9 to 45.7 months with HIPEC at interval debulking
- check_circleHIPEC added to interval debulking — after 3 cycles of carboplatin/paclitaxel — is the strongest evidence context
- check_circleCisplatin 100 mg/m² at 40°C for 90 minutes is the OVHIPEC standard protocol
- check_circleAccessible at specialist gynaecological oncology CRS-HIPEC centres in China and India via CancerFax
Why Ovarian Cancer and the Peritoneum Are Inseparable
Advanced ovarian cancer is, by its nature, a peritoneal disease. Unlike most solid tumours that spread via the bloodstream, ovarian cancer spreads predominantly by direct shedding of malignant cells from the ovarian surface into the peritoneal fluid — which then circulates and deposits cells across all peritoneal surfaces. This explains why 70–80% of patients with stage III–IV ovarian cancer have widespread peritoneal involvement at diagnosis.
“Ovarian cancer invented the concept of treating peritoneal surface malignancy surgically — interval debulking surgery preceded CRS-HIPEC by decades, and HIPEC is the logical next step in the same locoregional treatment philosophy.”
The Peritoneal-Plasma Barrier and HIPEC
Systemic carboplatin and paclitaxel reach ovarian cancer cells via the bloodstream — but the peritoneal-plasma barrier reduces peritoneal chemotherapy concentrations to 10–20× below plasma levels. Intraperitoneal cisplatin during HIPEC achieves concentrations 10–20× above plasma at the peritoneal surface — targeting the residual microscopic disease that systemic chemotherapy cannot reach after surgical debulking.
HIPEC in the Ovarian Cancer Treatment Pathway
HIPEC is most evidence-supported at the time of interval debulking surgery (IDS) — the surgical cytoreduction performed after 3 cycles of neoadjuvant carboplatin/paclitaxel (NACT). It is also being evaluated at primary debulking surgery (PDS) and at recurrence. The OVHIPEC-1 trial specifically addressed the IDS setting — the context where the majority of advanced ovarian cancer patients undergo surgery.
The OVHIPEC-1 Trial: Key Results
OVHIPEC-1 (van Driel et al., NEJM 2018) is the landmark RCT that established HIPEC as a standard-of-care addition to interval debulking surgery for advanced ovarian cancer.
OVHIPEC-1: Overall Survival (IDS ± HIPEC, Stage III Ovarian Cancer)
Source: van Driel WJ et al., N Engl J Med. 2018;378(3):230–240. Cisplatin 100 mg/m², 40°C, 90 min.
- Median OS: IDS + HIPEC45.7 mo
- Median OS: IDS alone33.9 mo
- Recurrence-free survival: IDS + HIPEC14.2 mo
- Recurrence-free survival: IDS alone10.7 mo
OVHIPEC-1: Safety and Complication Profile
Grade 3–4 adverse events; no statistically significant difference between arms
- Grade 3–4 adverse events: IDS + HIPEC27%
- Grade 3–4 adverse events: IDS alone25%
- 30-day readmission: IDS + HIPEC12%
- 30-day readmission: IDS alone13%
HIPEC Protocols for Ovarian Cancer
Multiple HIPEC regimens are used for ovarian cancer — cisplatin is the most evidence-based following OVHIPEC-1, but combination regimens are used at some centres.
| Protocol | Agent(s) | Dose | Temperature | Duration | Evidence Level |
|---|---|---|---|---|---|
| OVHIPEC-1 (standard) | Cisplatin | 100 mg/m² | 40°C | 90 min | |
| Cisplatin + paclitaxel | Cisplatin + paclitaxel | 75 mg/m² + 175 mg/m² | 41°C | 60 min | |
| Carboplatin | Carboplatin (when cisplatin contraindicated) | AUC 5–7 | 41°C | 90 min | |
| Oxaliplatin | Oxaliplatin | 460 mg/m² | 43°C | 30 min | |
| Mitomycin C | MMC | 15–35 mg total | 41°C | 90 min |
Who Is Eligible for HIPEC at Interval Debulking?
The OVHIPEC-1 inclusion criteria define the evidence-based eligibility framework — applied at specialist gynaecological oncology CRS-HIPEC centres.
| Criterion | OVHIPEC-1 Criteria / Standard Practice | Notes |
|---|---|---|
| Stage | Stage III ovarian cancer (FIGO IIIA–IIIC) | OVHIPEC-1 included stage III only; stage IV with limited extra-abdominal disease evaluated case-by-case |
| Histology | High-grade serous, endometrioid, or clear cell | Low-grade serous and mucinous histologies have different biology; discuss with specialist |
| Neoadjuvant chemotherapy | 3 cycles carboplatin/paclitaxel before IDS | Platinum-sensitive response (CA-125 reduction, imaging response) required before proceeding to IDS + HIPEC |
| Debulking intent | Complete or near-complete debulking anticipated | No survival benefit from HIPEC if CC-2 or CC-3 residual — complete cytoreduction is prerequisite |
| Performance status | WHO PS 0–2 | PS 3 — poor surgical candidate; discuss palliative systemic therapy |
| Renal function | GFR ≥50 mL/min for cisplatin HIPEC | Cisplatin nephrotoxicity — adequate hydration and GFR monitoring required; carboplatin if renal impairment |
| BRCA status | Does not affect HIPEC eligibility | BRCA1/2 mutation does not contraindicate or indicate HIPEC — PARP inhibitor maintenance follows HIPEC independently |
Key Clinical Numbers
Reference figures from OVHIPEC-1 and subsequent clinical practice.
- +11.8 moOS benefit from HIPEC at interval debulking (OVHIPEC-1)Median OS 45.7 vs 33.9 months — the largest single OS improvement demonstrated in a randomised trial for the IDS setting in advanced ovarian cancer at that time.
- 90 minHIPEC perfusion duration (OVHIPEC-1 protocol)Cisplatin 100 mg/m² perfused at 40°C for 90 minutes immediately after IDS completion — the protocol that achieved Level 1 evidence for OS benefit.
- No diffDifference in Grade 3–4 complications vs IDS aloneHIPEC did not increase severe adverse event rates — 27% vs 25% — a critical finding addressing the concern that HIPEC adds prohibitive toxicity to a major gynaecological operation.
- 70–80%Of advanced ovarian cancer patients have peritoneal diseasePeritoneal spread is the default pattern of ovarian cancer dissemination — making HIPEC a potentially relevant option for the majority of stage III–IV patients.
More from the Peritoneal Oncology Resource Library
Continue exploring CRS-HIPEC — from the foundational overview to other tumour types and access guides.
Frequently Asked Questions
Common questions from ovarian cancer patients exploring HIPEC.
About HIPEC for Ovarian Cancer
Is HIPEC now standard of care for all ovarian cancer patients having interval debulking?
OVHIPEC-1 established HIPEC as a standard-of-care option at interval debulking for stage III ovarian cancer — and many specialist gynaecological oncology centres now routinely offer it. However, adoption is not yet universal. Some centres and oncologists await further confirmatory data (the OVHIPEC-2 and CHORINE trials are ongoing). The discussion with your oncologist and gynaecological oncology surgeon should include whether your institution performs HIPEC at IDS and, if not, whether referral to a centre that does is appropriate. CancerFax can connect you with centres in China and India where HIPEC at IDS is routinely offered.
I have already had primary debulking surgery without HIPEC — can I still benefit from HIPEC at recurrence?
HIPEC at recurrence is a different and less well-evidenced context than HIPEC at IDS. Several Phase II trials have evaluated HIPEC at secondary cytoreduction for platinum-sensitive ovarian cancer recurrence — with encouraging but not yet Level 1 evidence. At specialist peritoneal oncology centres, HIPEC at recurrence is offered to selected patients with isolated peritoneal recurrence, adequate performance status, and platinum-sensitive disease. The decision requires careful multidisciplinary review — CancerFax can facilitate a specialist consultation to assess your recurrence pattern and eligibility.
My oncologist wants to start PARP inhibitor maintenance after chemotherapy. Does HIPEC conflict with this?
No — HIPEC and PARP inhibitor maintenance are not mutually exclusive. The OVHIPEC-1 trial was conducted before PARP inhibitors became standard maintenance, and patients in the trial did not uniformly receive them. In current practice, the sequence is: NACT (carboplatin/paclitaxel × 3 cycles) → IDS + HIPEC → completion chemotherapy (3 more cycles) → PARP inhibitor maintenance (olaparib, niraparib, or rucaparib based on BRCA/HRD status). The HIPEC step is inserted into an existing treatment pathway without replacing or delaying maintenance therapy. Discuss the complete treatment sequence with your gynaecological oncologist before scheduling surgery.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could HIPEC Improve Your Ovarian Cancer Outcomes?
CancerFax reviews your stage, surgical debulking status, platinum sensitivity, and BRCA status to assess whether HIPEC at interval debulking is appropriate — and connects you with specialist gynaecological oncology surgeons experienced in the OVHIPEC protocol.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.